> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-219/
- Published: 2019-04-14T12:00:00.000Z
- Updated: 2026-09-15T01:20:14.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5143866

[**Regulatory Review Period for Shionogi’s Symproic**](https://www.fdaweb.com/regulatory-review-period-for-shionogis-symproic/)  
*Federal Register* notice: FDA determines the regulatory review period for Shionogi’s Symproic (naldemedine tosylate) for treating opioid-induced constipation in adult patients with chronic non-cancer pain. 04/12/2019

[**Class 2 for Ventilatory Electrical Impedance Tomograph**](https://www.fdaweb.com/class-2-for-ventilatory-electrical-impedance-tomograph/)  
*Federal Register* notice: Based on a de novo request, FDA classifies Timpel’s Enlight 1810 ventilatory electrical impedance tomograph into Class 2\. 04/12/2019

[**Device Accessories Into Class 1**](https://www.fdaweb.com/device-accessories-into-class-1/)  
*Federal Register* notice: FDA classifies suitable medical device accessories into Class I as required by the FDA Reauthorization Act of 2017\. 04/12/2019

[**Final Rule on OTC Hand Sanitizers**](https://www.fdaweb.com/final-rule-on-otc-hand-sanitizers/)  
*Federal Register* final rule: FDA rules that certain active ingredients are not allowed to be used in OTC hand sanitizers. 04/11/2019

[**Comments Extended on Tobacco Compliance Policy Guide**](https://www.fdaweb.com/comments-extended-on-tobacco-compliance-policy-guide/)  
*Federal Register* notice: FDA extends the comment period on a draft guidance entitled “Modifications to Compliance Policy for Certain Deemed Tobacco Products.” 04/09/2019

[**Oncologic Drugs Panel to Discuss 2 Daiichi NDAs**](https://www.fdaweb.com/oncologic-drugs-panel-to-discuss-2-daiichi-ndas/)  
*Federal Register* notice: FDA announces a 5/14 Oncologic Drugs Advisory Committee meeting to discuss two Daiichi Sankyo NDAs. 04/08/2019

[**Panel to Discuss Drug Renal Impairment Evaluations**](https://www.fdaweb.com/panel-to-discuss-drug-renal-impairment-evaluations/)  
*Federal Register* notice: FDA announces a 5/7 Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting. 04/08/2019

[**Antivert Not Withdrawn Due to Safety/Efficacy: FDA**](https://www.fdaweb.com/antivert-not-withdrawn-due-to-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Casper Pharma’s Antivert (meclizine hydrochloride) chewable tablets were not withdrawn from sale for reasons of safety or effectiveness. 04/08/2019

[**Final Guide on REMS Factors**](https://www.fdaweb.com/final-guide-on-rems-factors/)  
*Federal Register* notice: FDA makes available a final guidance entitled “Risk Evaluation and Mitigation Strategy: FDA’s Application of Statutory Factors in Determining When a Risk Evaluation and Mitigation Strategy Is Necessary.” 04/05/2019

[**Cortisporin Not Withdrawn Due to Safety/Efficacy: FDA**](https://www.fdaweb.com/cortisporin-not-withdrawn-due-to-safety-efficacy-fda/)  
*Federal Register* notice: FDA determines that Monarch Pharmaceuticals’ Cortisporin (hydrocortisone/neomycin sulfate/polymyxin B sulfate) was not withdrawn from sale for reasons of safety or effectiveness. 04/05/2019